Abenacianine for injection (VGT-309) originated in the Bogyo Lab within the Department of Pathology at the Stanford University School of Medicine.
About the Inventor
Dr. Matthew Bogyo received a B.Sc. in Chemistry from Bates College in 1993 and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology in 1997. Following completion of his doctoral studies, he was appointed as a Faculty Fellow in the Department of Biochemistry and Biophysics at the University of California, San Francisco (UCSF). From 2001 to 2003, Dr. Bogyo served as Head of Chemical Proteomics at Celera Genomics while maintaining an Adjunct Faculty appointment at UCSF.
Matthew Bogyo
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
In 2003, Dr. Bogyo joined the Department of Pathology at Stanford University School of Medicine and was subsequently appointed to the faculty in the Department of Microbiology and Immunology in 2004. His research focuses on the application of chemical biology approaches to study the role of proteases in human disease.
​
In particular, his laboratory investigates the role of cysteine proteases in tumorigenesis as well as in the life cycles of human parasites and bacterial pathogens.
Dr. Bogyo currently serves on the editorial boards of Biochemical Journal, Cell Chemical Biology, and Molecular and Cellular Proteomics. He also consults for several biotechnology and pharmaceutical companies in the San Francisco Bay Area and is a founder and board member of Akrotome Imaging.
​
​